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Abstract The impact of postoperative atrial ﬁbrillation
(PAF) on patient outcomes has prompted intense investi-
gationintotheoptimalmethodsforpreventionandtreatment
of this complication. In the prevention of PAF, b-blockers
and amiodarone are particularly effective and are recom-
mended by guidelines. However, their use requires caution
due to the possibility of drug-related adverse effects. Aside
from these risks, perioperative prophylactic treatment with
statins seems to be effective for preventing PAF and is
associated with a low incidence of adverse effects. PAF can
be treated by rhythm control, heart-rate control, and anti-
thrombotic therapy. For the purpose of heart rate control, b-
blockers, calcium-channel antagonists, and amiodarone are
used. In patients with unstable hemodynamics, cardiover-
sion may be performed for rhythm control. Antithrombotic
therapy isusedinadditiontoheart-rate maintenancetherapy
in cases of PAF[48-h duration or in cases with a history of
cerebrovascular thromboembolism. Anticoagulation is the
ﬁrst choice for antithrombotic therapy, and anticoagulation
management should focus on maintaining international
normalized ratio (INRs) in the 2.0–3.0 range in patients
\75 yearsofage,whereasprothrombin-timeINR shouldbe
controlled to the 1.6–2.6 range in patients C75 years of age.
In the future, dabigatran could be used for perioperative
management of PAF, because it does not require regular
monitoring and has a quick onset of action with short serum
half-life. Preventing PAF is an important goal and requires
speciﬁc perioperative management as well as other approa-
ches. PAF is also associated with lifestyle-related diseases,
which emphasizes the ongoing need forappropriate lifestyle
management in individual patients.
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Introduction
Postoperative atrial ﬁbrillation (PAF) is the most frequent
complication that occurs after cardiovascular surgery
(Table 1)[ 1]. The incidence of cardiovascular events, such
as cerebral infarction and heart failure, increases by two-
fold in the presence of chronic atrial ﬁbrillation (AF) [2].
Conventional viewpoints suggest that PAF is less likely to
affect the survival of patients when compared with chronic
AF, although it does slightly prolong the duration of hos-
pital stay. However, reports suggest that PAF is associated
with a signiﬁcant incidence of various complications,
including cardiovascular events, renal failure, infection,
and cerebral infarction [3]. PAF is affected by diverse
factors, and a wide variety of strategies has been shown to
be useful in preventing or treating PAF. This article out-
lines the etiology, characteristics, and PAF prevention and
treatment, citing the latest ﬁndings from published reports.
PAF characteristics
AF is the most frequent complication arising after coronary
artery bypass (CAB) surgery, occurring in 30% of cases.
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valve-replacement surgery (30–40%) and after compound
operative procedures (40–60%) [4]. The onset of AF has
also been reported after nonheart surgery, such as pul-
monary lobectomy (10–20%) and total pneumonectomy
(40%) [5]. PAF most frequently develops on the second
postoperative day. Although often transient, it recurs in
40% of cases [3]. Historically, in contrast to chronic AF,
PAF was thought to be relatively unlikely to affect patient
survival. However, more recent studies suggest that PAF
increases the duration of intensive care unit (ICU) stay
(2.0 days in the no-PAF group vs. 3.6 days in the PAF
group, p\0.001), duration of hospital stay (7 days in the
no-PAF group vs. 10 days in the PAF group, p\0.001),
and is associated with a twofold elevation in the incidence
of cerebral infarction (2.4% in the no-PAF group vs. 5.3%
in the PAF group, p\0.001) and a increased risk of
30-day mortality (3.0% in the no-PAF group vs. 6.0% in
the PAF group, p\0.001). Furthermore, PAF was an
independent predictor of long-term mortality [adjusted
odds ratio (OR) 1.5, p\0.001] in a retrospective cohort;
OR 3.4, p\0.0018 in a case-matched population. [4].
Thus, PAF appears to have a signiﬁcant effect on the acute
postoperative condition of patients as well as on their long-
term prognosis.
Preoperative factors associated with an increased risk of
developing PAF are summarized in Table 2. The incidence
of PAF is particularly high among elderly patients [4, 6, 7],
especially in those[70 years of age [8]. Conventional risk
factors for PAF include left atrial dilatation and left ven-
tricular hypertrophy [7, 8]; other risk factors include dia-
betes mellitus [7, 8], obesity, and metabolic syndrome [9].
A recent study reported that obesity is an independent risk
factor for PAF in those undergoing cardiovascular surgery,
especially in patients [50 years of age [10, 11]. Intraop-
erative risk factors for PAF are summarized in Table 3 and
include atrial injury, atrial ischemia, insertion of a vascular
catheter, and sudden changes in circulating blood volume
[7–9]. Furthermore, cardiovascular surgery using cardio-
pulmonary bypass is likely to induce an inﬂammatory
reaction, triggering the onset of PAF [12]. Postoperative
risk factors for PAF are summarized in Table 4 and include
volume overload, electrolyte abnormalities, atrial extra-
systole, and sympathetic hyperactivity [10]. In addition,
studies suggest that inﬂammatory reactions are a risk factor
for PAF [13, 14]. Delineation of these novel risk factors for
PAF has led to the development of new strategies for
treating and preventing PAF.
Preventing PAF
Conventionally, nondihydropyridine calcium-channel
antagonists and digitalis have been used for treating PAF
[15, 16]. Although nondihydropyridine calcium-channel
antagonists are effective against supraventricular tachy-
cardia [17], they are also frequently associated with
adverse reactions (e.g., atrioventricular block, heart failure,
etc.) [18] and are therefore not the ideal agents to use for
prophylactic purposes. Further, one meta-analysis reported
that digitalis was ineffective when used for PAF preven-
tion. This is probably because digitalis acts on vagal tone
and therefore reduces the ventricular rate during atrial
arrhythmias. Therefore, this beneﬁt of digitalis may be
attenuated during the perioperative period, in which there
is increased sympathetic tone [19]. Methods reported to be
useful in PAF prevention are summarized in Table 5.
Table 1 Postoperative complications after coronary artery bypass
grafting
Complication Percent of patients
Rethoracotomy 2
Renal failure 5
Cerebral infarction 2.5
Respiratory failure 6
Gastrointestinal failure 2
Atrial ﬁbrillation 30
Table 2 Preoperative risk factors for postoperative atrial ﬁbrillation
Risk factors
Old age Diabetes
Enlargement of the left atrium Obesity
Left ventricular hypertrophy Metabolic syndrome
Hypertension
Table 3 Intraoperative risk factors for postoperative atrial ﬁbrillation
Risk factors
Damage to the atrium Insertion of a ventilator tube
Myocardial ischemia Venous cannulation
Acute volume change
Table 4 Postoperative risk factors for postoperative atrial ﬁbrillation
Risk factors
Volume overload Atrial extrasystole
Increased afterload Imbalance of the autonomic nervous system
Hypotension Electrolyte imbalance
Inﬂammation
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b-blockers have direct antiarrhythmic activity on stimulus
conduction cells and myocardial cells and are classiﬁed as
class II antiarrhythmic agents according to the Vaughan–
Williams classiﬁcation. b-blockers are effective against
tachycardic arrhythmia [20], supraventricular arrhythmia
[21], and lidocaine-resistant ventricular ﬁbrillation [22].
Perioperative prophylactic use of b-blockers could
decrease cardiovascular events [23–31]. Coleman et al.
[32] reported that postoperative b-blockers reduced hos-
pital length of stay [mean ± standard deviation (SD)
10.22 ± 11.38 in the b-blocker group vs. 12.40 ± 15.67 in
the placebo group; p = 0.001] and PAF (23.5% in the b-
blocker group vs. 28.4% in the placebo group; p = 0.02).
Crystal et al. [33] reported that b-blockers had the greatest
magnitude of effect for PAF prevention in a meta-analysis
[OR 0.35; 95% conﬁdence interval (CI) 0.26–0.49]. Lin-
denauer et al. [34] reported that prophylactic b-blockers
were associated with a reduced risk of in-hospital death in
patients with a Revised Cardiac Risk Index (RCRI, which
is based on the presence of history of ischemic heart dis-
ease, cerebrovascular disease, renal insufﬁciency, diabetes
mellitus, or a patient undergoing high-risk surgery) of score
C3 but not in patients with a RCRI score of 2, l, or 0. Thus,
that study demonstrated an association between improved
outcomes and the use of b-blockers in clinically high-risk
patients, whereas lower-risk patients had worse outcomes.
The PeriOperative Ischemia Study Evaluation (POISE)
trial [35], which was a large, randomized, controlled trial
of ﬁxed, high-dose, extended-release metoprolol starting on
the day of surgery in more than 8,000 patients undergoing
noncardiac surgery, demonstrated that perioperative b-
blocker treatment reduced the incidence of cardiovascular
events [5.8% patients in the metoprolol group vs. 6.9%
patients in the placebo group; hazard ratio (HR) 0.84; 95%
CI 0.70–0.99; p = 0.04] but increased the total death rate
(3.1 vs. 2.3%; HR 1.33, 95% CI 1.03–1.74; p = 0.03) or
the incidence of stroke (1.0 vs. 0.5%; HR 2.17; 95% CI
1.26–3.74; p = 0.005), possibly due to b-blocker-induced
hypotension (15 vs. 9.7%; HR 1.55; 95% CI 1.38–1.74)
and bradycardia (6.6 vs. 2.4%; HR 2.74; 95% CI
2.19–3.43). Further, a meta-analysis of data from 33 ran-
domized controlled trials (RCTs) reported that b-blocker
treatment reduced nonfatal myocardial infarction (MI) (OR
0.65; 95% CI 0.54–0.79) and myocardial ischemia (OR
0.36; 95% CI 0.26–0.50) but increased nonfatal strokes
(OR 2.01; 95% CI 1.27–3.68) and the incidence of bra-
dycardia (OR 3.13; 95% CI 2.51–3.92) and hypotension
(OR 1.69; 95% CI 1.39–2.65) that required treatment [36].
These data suggest that prophylactic b-blockers should be
used with caution. Guidelines for using b-blockers were
updated after results from the POISE trial became avail-
able. At present, unless contraindicated, treatment with b-
blockers is recommended to prevent PAF [Class I, level of
evidence (LOE) A; Table 6] in the American College of
Cardiology (ACC)/American Heart Association (AHA)/
European Society of Cardiology (ESC) Guidelines for the
Management of Patients with Atrial Fibrillation [37].
Further, preoperative or early postoperative administration
of b-blockers in patients without contraindications should
be used as standard therapy to reduce the incidence and/or
clinical sequelae of AF and is recommended in the ACC/
AHA Guideline Update for Coronary Artery Bypass Graft
Surgery (Class I, LOE B; Table 6)[ 38]. The POISE trial
did not study continuation of b-blockers in patients
Table 5 Prevention of postoperative atrial ﬁbrillation
Preventive measures
b-blockers Steroids
Amiodarone Statins
OPCAB Pacing
OPCAB off-pump coronary artery bypass grafting
Table 6 Classiﬁcation of recommendations
ACC/AHA/ESC guideline recommendations
Class
Class I Conditions for which there is evidence and/or
general agreement that a given procedure/
therapy is beneﬁcial, useful, and effective
Class II Conditions for which there is conﬂicting evidence
and/or a divergence of opinion about the
usefulness/efﬁcacy of performing the procedure/
therapy
Class IIa Weight of evidence/opinion is in favor of
usefulness/efﬁcacy
Class IIb Usefulness/efﬁcacy is less well established by
evidence/opinion
Class III Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not
useful or effective and in some cases may be
harmful
Level of evidence
Level of
evidence A
Data derived from multiple randomized clinical
trials or meta-analyses
Level of
evidence B
Data derived from a single randomized trial, or
nonrandomized studies
Level of
evidence C
Only consensus opinion of experts, case studies, or
standard of care
Classiﬁcation of recommendations and level of evidence are expres-
sed in the ACC/AHA/ESC format. Recommendations are evidence
based and derived primarily from published data
Weight of evidence is ranked from highest (A) to lowest (C)
ACC American College of Cardiology, AHA American Heart
Association, ESC European Society of Cardiology
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123undergoing surgery who are receiving b-blockers for the
ACC/AHA Class I guideline indications. The guidelines on
perioperative cardiovascular evaluation and care for
noncardiac surgery also state that b-blockers should be
continued in patients undergoing surgery who are receiving
b-blockers for treatment of conditions with ACC/AHA
Class I guideline indications for the drugs (Class I, LOE C;
Table 6)[ 39].
Amiodarone
Amiodarone is a multichannel blocker possessing a, b,
potassium(K
?)channel,sodium(Na
?)andcalcium(Ca
2?)-
blocking actions. It is a Class III antiarrhythmic agent
according to the Vaughan–Williams classiﬁcation. Amio-
darone regimens are used to prevent or treat PAF. In one
report, a 1-week preoperative oral regimen decreased the
incidence of PAF (25% patients in the amiodarone group vs.
53% patients in the placebo group, p = 0.03) [40], postop-
erative intravenous treatment decreased the incidence of
PAF when compared with placebo (35% patients in the
amiodarone group vs. 47% patients in the placebo group,
p = 0.01) [41], and treatment throughout the perioperative
period decreased the incidence of PAF when compared with
placebo (16% patients in the amiodarone group vs. 25%
patients in the placebo group, p = 0.001) [42]. Amiodarone
is also recommended as an appropriate means of preventing
AF in high-risk patients (LOE A, Class IIa; Table 6)[ 37].
However,ameta-analysisofrandomizedplacebo-controlled
trials showed that perioperative amiodarone treatment was
associated with an increase in the incidence of adverse
reactions (1.7-fold in bradycardia and 1.6-fold in hypoten-
sion) [43]. Risk factors for amiodarone-related adverse
reaction included intravenous administration, and adminis-
tration of[1 g per day [43]. In view of these ﬁndings, it is
advisable to avoid prophylactic amiodarone treatment in
patients at low risk for developing PAF. In those who do
requireprophylactictreatment,cliniciansshouldbeawareof
the potential for adverse reactions (bradycardia, hypoten-
sion, etc.) during the use of this drug. b-blockers and ami-
odarone are particularly effective for perioperative
prophylactic treatment and are recommended for this pur-
pose in the Medical Society guidelines [37–39]. Otherwise,
clinicians should be cognizant that there is a risk of drug-
related adverse reactions, particularly bradycardia and
hypotension, when using these drugs.
Statins
Autopsy studies have demonstrated the role of plaque
rupture and erosion in the pathophysiology of acute coro-
nary syndrome. Statins have pleiotropic action, includ-
ing the modiﬁcation of atherosclerotic plaques and the
improvement of endothelial function. Inﬂammation plays a
role in the pathogenesis of atherosclerosis, and the anti-
inﬂammatory properties of stains likely account for their
ability to reduce the incidence of PAF and perioperative
cardiovascular events [44, 45]. Mariscalco et al. reported
that PAF occurred in 29.5% of patients receiving preop-
erative statin therapy when compared with 40.9% of
patients who were not receiving such therapy (p = 0.021).
Preoperative statins were associated with a 42% reduction
in the risk of AF development after CAB surgery (OR 0.58;
95% CI 0.37–0.91, p = 0.017, stratiﬁed by propensity
score) [46]. A meta-analysis of randomized trials of the use
of preoperative statins reported that statins signiﬁcantly
reduced postoperative MI [risk ratio (RR) 0.57; CI
0.46–0.70; p\0.0001], and PAF (RR 0.54; 95% CI
0.43–0.68; p\0.0001) [47]. Guidelines do not speciﬁcally
recommend the use of statins before cardiovascular surgery
for the express purpose of preventing periprocedural
complications, such as PAF. However, at present, periop-
erative prophylactic treatment with statins that have few
side effects seems to be appropriate for PAF prevention of
PAF.
Anti-inﬂammatory drugs
Cardiovascular surgery with cardiopulmonary bypass is
associated with a systemic inﬂammatory response, which
may be in part responsible for PAF. Patients with PAF tend
to have signiﬁcantly higher C-reactive protein (CRP),
higher white blood cell (WBC) counts, and higher levels of
inﬂammatory cytokines when compared with patients who
do not develop PAF [48, 49]. This ﬁnding suggests that
inﬂammatory reactions may be important in the pathogen-
esis of PAF [48, 49]. In nonsurgical patients, corticosteroid
treatment may reduce the incidence of recurrent AF.
Halonen et al. [50] reported that the administration of
100 mg of hydrocortisone reduced PAF when compared
with placebo in a randomized control trial (30% in the
100-mg hydrocortisone group vs. 48% in the placebo group;
adjusted HR 0.54; 95% CI 0.35–0.83, p = 0.004). Corti-
costeroids have anti-inﬂammatory properties. Several
studies have indicated that the postoperative concentration
of CRP was signiﬁcantly lower in patients who received
hydrocortisone than in patients who did not. Corticosteroids
also reduce postoperative nausea, vomiting, and anorexia.
Thus, corticosteroid therapy may improve absorption of
orally administered medications, such as b-blockers, and
thereby reduce the incidence of PAF. Cheruku et al.
administrated 30 mg ketorolac intravenously every 6 h
until patients were able to take medications orally; then,
patients were switched to ibuprofen 600 mg orally three
times a day for a total of 7 days or until discharge, which-
ever was longer [nonsteroidal anti-inﬂammatory drug
432 J Anesth (2012) 26:429–437
123(NSAID) group]. The authors reported that NSAIDs
reduced the incidence of PAF (9.8% vs. 28.6% in the pla-
cebo group) [51]. However, NSAIDs are associated with
nephrotoxicity, particularly when used in the postoperative
period, and in elderly patients.
Magnesium
Some studies have reported that serum magnesium levels
are low in patients who develop PAF [52] and that tachy-
cardia arrhythmia is closely related to the magnesium level
[53]. A meta-analysis demonstrated that magnesium
administration decreased the proportion of patients devel-
oping postoperative AF from 28% in the control group to
18% in the treatment group (OR 0.54; 95% CI 0.38–0.75)
[54]. In another meta-analysis, magnesium prevented PAF
(OR 0.57; 95% CI 0.42–0.77), but there was signiﬁcant
heterogeneity (p\0.001) [29]. These meta-analyses
included a small number of patients, and the design varied
among the different studies, which limits the interpretation
of the results. Although there are some data to suggest that
perioperative administration of magnesium can prevent
PAF in a manner similar to perioperative treatment with
antiarrhythmic drugs, this notion remains controversial.
Off-pump coronary artery bypass grafting (OPCAB)
CAB surgery can be divided into procedures that use
extracorporeal circulation and those that do not (OPCAB).
OPCAB requires less manipulation of the aorta and avoids
the use of cardiopulmonary bypass and may therefore
cause less postoperative complications [55]. The incidence
of PAF is lower following OPCAB when compared with
conventional CAB surgery using cardiopulmonary bypass
(OR 0.78; 95% CI 0.74–0.82; p\0.0001 in an observa-
tional study; OR 0.59; 95% CI 0.46–0.77; p\0.0001 in a
randomized controlled study) [55]. However, revasculari-
zation procedures did not affect postoperative mortality or
stroke rates in a recent cohort study [56] and did not affect
the incidence of PAF in a recent randomized trial [57]. In
high-risk patients, Moller et al. [58] reported that the
incidence of cardiovascular events, including PAF, was
similar when comparing on-pump and off-pump revascu-
larization. Thus, it remains controversial whether or not
OPCAB reduces the incidence of PAF.
Atrial pacing
Prophylactic atrial pacing to prevent PAF after cardiovas-
cular surgery is based on the fact that pacing is thought to
favorably inﬂuence intra-atrial conduction and atrial
refractoriness. There are several mechanisms by which
atrial pacing might prevent AF: reduction of the
bradycardia-induced dispersion of atrial repolarization,
avoidance of the trigger for AF by overdrive suppression,
and changing atrial activation pattern by dual-site atrial
pacing [10]. Meta-analyses have demonstrated that single-
site atrial pacing and biatrial pacing can reduce the inci-
dence of PAF [29, 33, 59]. Fan et al. [60] compared these
two methods of atrial pacing and reported that biatrial
pacing was superior in terms of maintaining interatrial
conduction and is thus more useful in terms of preventing
PAF than single-site atrial pacing. However, the number of
enrolled patients was small, and the protocols varied widely
among studies. Indeed, a major adverse effect of prophy-
lactic atrial pacing is its potential proarrhythmic effect,
which might be precipitated by inappropriate sensing or loss
of pacing through temporary wires. Further, biatrial pacing
requires complex manipulations, which has limited its use
as a means of preventing AF to only a small number of
facilities. Further study is required to evaluate the utility of
atrial pacing in PAF prevention.
Treating PAF
PAF is typically transient and often requires no treatment.
However, therapeutic intervention is neededin patients with
compromised heart function, duration of AF [48 h, and
high-risk patients with cerebral thromboembolism [37, 38,
61]. PAF can be treated by rhythm control, heart-rate con-
trol, and antithrombotic therapy, similar to the methods
used for treating chronic AF. The Atrial Fibrillation Follow-
Up Investigation of Rhythm Management (AFFIRM) study
[62], which compared multiple methods of treatment for
chronic AF, and the Rate Control versus Electrical (RACE)
cardioversion for persistent atrial ﬁbrillation trial [63] found
that rate control was not inferior to rhythm control for
preventing death and morbidity because antiarrhythmic
agents used for rhythm control are associated with various
adverse effects, including cardiac depression and a para-
doxical increase in dangerous arrhythmias. Rate control
with pharmacologic agents (either a b-blocker or a nondi-
hydropyridine calcium-channel antagonist, in most cases) is
recommended for patients with persistent or permanent AF.
In the acute setting, intravenous administration of b-
blockers (esmolol, metoprolol, or propranolol) or nondi-
hydropyridine calcium-channel antagonists (verapamil,
diltiazem) and amiodarone is recommended in order to slow
the ventricular response to AF, exercising caution in
patients with hypotension or heart failure [64]. b-blockers
are more effective than calcium-channel antagonists for
controlling the ventricular response during AF [65]. Fur-
ther, b-blockers accelerate the conversion of postoperative
supraventricular arrhythmias to sinus rhythm when com-
pared with calcium-channel antagonists [21]. Cardioversion
J Anesth (2012) 26:429–437 433
123of AF is generally not recommended for asymptomatic or
minimally symptomatic arrhythmias until the underlying
problem is corrected. Indeed, correcting the underlying
problem alone frequently leads to a spontaneous return to
normal sinus rhythm (Class I, LOE A) [37]. In patients with
stable hemodynamics, heart rate maintenance therapy is
recommended. b-blockers, calcium-channel antagonists,
and amiodarone are used to control heart rate. The target
heart rate is 60–80/min at rest and 90–115/min during
exercise. During the perioperative period, it is advisable to
control heart rate at 90–115/min, similar to the range rec-
ommended for rate control during exercise [37].
PAF results in loss of the ‘‘atrial kick’’ and a 20–30%
reduction in cardiac output. In patients with unstable
hemodynamics (often seen after cardiovascular surgery),
sinus rhythm is advantageous, and maintaining or restoring
sinus rhythm is recommended [37]. It is recommend to
restore sinus rhythm by pharmacologic cardioversion with
ibutilide or via direct current cardioversion in patients who
develop postoperative AF (Class IIa, LOE B) [37]. In the
highly symptomatic patient or when rate control is difﬁcult
to achieve, cardioversion may be performed using the same
precautions regarding anticoagulation as in nonsurgical
cases. A variety of pharmacologic agents, including ami-
odarone, procainamide, ibutilide, and sotalol, may be
effective to convert AF to sinus rhythm. Although a Class
III agent was more effective than placebo for postoperative
AF treatment in one study, orally administered sotalol is
appealing in this situation because its b-blocking action
slows the ventricular rate and its proarrhythmic toxicity is
relatively low. However, this agent seems less effective
than others for AF conversion. Otherwise, ﬂecainide, dof-
etilide, ibutilide, propafenone (Class I, LOE A), and ami-
odarone (Class IIa, LOE A) are recommended for
pharmacologic cardioversion. If these drugs are not effec-
tive, direct-current cardioversion can be performed. Anti-
arrhythmic medications should also be administered in an
attempt to maintain sinus rhythm in patients with recurrent
or refractory PAF. Dofetilide (Class I, LOE A) and amio-
darone and ibutilide (Class IIa, LOE A) are recommended
for maintaining sinus rhythm [37].
PAFisassociatedwithanincreasedriskofcardiovascular
and cerebrovascular events, especially strokes [3, 66].
Antithrombotic therapy is used in addition to heart-rate
maintenance therapy in cases of PAF[48-h duration or in
caseswithahistoryofcerebrovascularthromboembolism.In
contrast, anticoagulation in the perioperative period might
increase the risk of bleeding or cardiac tamponade [67].
Antithrombotic agent selection should be based upon the
absoluterisksofstrokeandbleedingandtherelativeriskand
beneﬁt fora given patient. Anticoagulationismoreeffective
than aspirin to prevent stroke in patients with AF, as sug-
gested by indirect comparisons and by a 33% risk reduction
(95% CI 0.13–0.49) in a meta-analysis. Randomized trials
involving high-risk AF patients (stroke rates[6% per year)
show larger relative risk reductions in response to adjusted-
dose orally administered anticoagulation therapy relative to
aspirin, whereas the relative risk reductions are consistently
smaller in trials of AF patients with lower stroke rates [68].
Thus, the ﬁrst choice for antithrombotic therapy is antico-
agulation. In those with contraindications to orally admin-
istered anticoagulation therapy, aspirin 81–325 mg daily is
recommended as an alternative to vitamin K antagonists
[37]. One meta-analysis reported that adjusted-dose orally
administered anticoagulation threapy is highly efﬁcacious
for stroke prevention, with a risk reduction of 62% (95% CI
0.48–0.72) versus placebo in an intention to treat analysis
[68]. Protection against stroke due to AF is achieved at a
prothrombin-time international normalized ratio (PT-INR)
range of 2.0–3.0 [69]. For patients without mechanical
heart valves who are at high risk of stroke, chronic anti-
coagulant therapy orally with a vitamin K antagonist is
recommended in a dose-adjusted manner to achieve the
target intensity PT-INR of 2.0–3.0, unless contraindicated
[69]. Factors associated with highest risk for stroke in
patients with AF are prior thromboembolism (e.g., stroke,
transient ischemic attacks, or systemic embolism) and
rheumatic mitral stenosis (Class I, LOE A) [37]. Although
the optimal duration of antithrombotic therapy has not
been established, in general, if normal sinus rhythm
returns, anticoagulation therapy can be stopped because its
risks outweigh the beneﬁts [61]. The risk of bleeding is
higher in elderly patients receiving antithrombotic ther-
apy. PT-INR should be controlled to 1.6–2.6 in patients
C75 years of age [37]. In the clinical setting, anticoagu-
lation therapy must be started when the risk–beneﬁt ratio
is favorable, especially in high-risk patients (e.g., elderly
patients or those with uncontrolled hypertension or a
history of bleeding). In the recent Randomized Evaluation
of Long-Term Anticoagulation Therapy (RE-LY) trial,
dabigatran administered at a dose of 150 mg was associ-
ated with lower rates of stroke and systemic embolism
(relative risk 0.66; 95% CI 0.53–0.82; p\0.001), but a
similar rate of major hemorrhage (relative risk 0.93; 95%
CI 0.81–1.07; p = 0.31) when compared with warfarin
[70]. Although dabigatran is not a vitamin K antagonist, it
is a potent, direct, competitive inhibitor of thrombin [70].
Another advantage of dabigatran is its lack of interactions
with food and drugs. In addition, dabigatran does not
require regular monitoring, and it has a quick onset of
action and a short serum half-life [71]. In the future, use
of dabigatran for perioperative management of PAF is
expected to increase.
The impact of PAF on patient outcomes has prompted
intense investigation into the optimal methods for preven-
tion and treatment of this complication. PAF prevention
434 J Anesth (2012) 26:429–437
123is an important goal and requires speciﬁc perioperative
management as well as other approaches. PAF is also
associated with obesity, diabetes mellitus, and metabolic
syndrome, which emphasizes the ongoing need for appro-
priate lifestyle management in individual patients.
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